Labelling Magazine Packaging 
Pharmaceutical Technology
JUNE 25, 2025
The updated label for GE HealthCare’s positron emission tomography (PET) imaging agent Vizamyl (flutemetamol F 18 injection) now includes quantification of amyloid in the brain, meaning patients taking an anti-amyloid therapy can be monitored for the drug’s effectiveness. Can pharma tariffs “Make America Manufacture Again”?
Pharmaceutical Technology
JUNE 18, 2025
Subjects who conclude the trial will be qualified for an open-label extension trial. Can pharma tariffs “Make America Manufacture Again”? All subjects will be given zagociguat in one of the 12-week durations and a placebo during the other. Give your business an edge with our leading industry insights.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 23, 2025
Bayer has responded by eying a label extension that would allow injections of its high-dose version in intervals of up to six months. Can pharma tariffs “Make America Manufacture Again”? Vabysmo generated $4.3bn in sales in 2024, becoming one of Roche’s top-selling drugs, and had high year-over-year growth than Eylea.
Pharmaceutical Technology
JUNE 26, 2025
It also identifies off-label usage patterns and relevant comorbidities that may influence therapeutic decisions. Can pharma tariffs “Make America Manufacture Again”?
GMPSOP
FEBRUARY 10, 2024
GMP/GLP and PPE training are applied to all employees, contractors and casual staff working in a GMP environment, including manufacturing, packaging, labelling, distribution, QA, QC, development, validation, engineering, IT staff and anyone whose activities could affect product quality. </p>
Pharmaceutical Technology
JUNE 27, 2025
June 27, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Label updates have been approved for BMS’ CAR T cell therapies, Breyanzi and Abecma, to treat multiple myeloma. The regulatory agency has also given approval to the removal of the REMS requirement from the product labels. Credit: Saiful52 / Shutterstock.
Pharmaceutical Technology
JUNE 13, 2025
The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir) for treating adults and paediatric patients three years and older with acute or chronic hepatitis C virus (HCV) infection. Can pharma tariffs “Make America Manufacture Again”? Credit: © AbbVie Inc. All rights reserved.
Expert insights. Personalized for you.
52 
Let's personalize your content